| Age (y.o.) |
30.49 ± 8.46 (16-47) |
| SLEDAI score |
12.85 ± 5.67 (6-26) |
| Disease duration (months) |
26.44 ± 24.92 (2-96) |
| Percentage of patients receiving glucocorticoid treatment |
100% |
| Current glucocorticoid dose (mg/day) |
26,87 ± 17,96 (4-48) |
| Percentage of patients receiving Immunosuppresant |
| Methotrexate |
7.69% |
| Azathioprin |
10.25% |
| Chloroquin |
12.82% |
| Mycophenolate mofetil |
12.82% |
| Cyclophosphamid |
5.13% |
| Percentage of clinical manifestation |
| Malar rash |
46.15% |
| Oral ulcers |
30.77% |
| Arthritis |
43.59% |
| Pleuritis or pericarditis |
17.95% |
| Renal disorder |
48.72% |
| Neurologic disorder |
2.56% |
| Hematologic disorder |
7.69% |
| Immunologic disorder |
100% |
